EVI1 expression in acute myeloid leukaemia

SE Langabeer, JR Rogers, G Harrison, Keith Wheatley, H Walker, BJ Bain, AK Burnett, AH Goldstone, DC Linch, D Grimwade

Research output: Contribution to journalArticle

47 Citations (Scopus)


Acute myeloid leukaemia (AML) with 3q26 cytogenetic abnormalities is associated with overexpression of EVI1, dysmegakaryopoiesis and poor prognosis. Screening for EVI1 transcripts was performed in 336 cases of AML, including 139 patients with acute promyelocytic leukaemia (APL). Expression was detected in 7 out of 10 cases with and 23 out of 326 without 3q26 abnormalities including one APL case. Among cases lacking 3q abnormalities, detection of EVI1 transcripts was neither associated with characteristic dysmegakaryopoietic features, nor predictive of a poor outcome, indicating that screening will probably not assist in treatment stratification. This study nevertheless demonstrates that deregulation of EVI1, although rare in APL, is a relatively frequent event in AML.
Original languageEnglish
Pages (from-to)208-211
Number of pages4
JournalBritish Journal of Haematology
Issue number1
Publication statusPublished - 1 Jan 2001


  • EVI1
  • APL
  • 3q26
  • clinical trials
  • AML


Dive into the research topics of 'EVI1 expression in acute myeloid leukaemia'. Together they form a unique fingerprint.

Cite this